Efficacy of B-Cell Targeted Therapy With Rituximab in Patients With Active Moderate to Severe Graves' Orbitopathy: A Randomized Controlled Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of B-Cell Targeted Therapy With Rituximab in Patients With Active Moderate to Severe Graves' Orbitopathy: A Randomized Controlled Study

Published:2015-02 Issue:2 Volume:100 Page:422-431
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:The Journal of Clinical Endocrinology & Metabolism

Author:

Salvi Mario,Vannucchi Guia,Currò Nicola,Campi Irene,Covelli Danila,Dazzi Davide,Simonetta Simona,Guastella Claudio,Pignataro Lorenzo,Avignone Sabrina,Beck-Peccoz Paolo

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Cited by 301 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring autoimmune endocrine diseases induced by monoclonal antibodies used as multiple sclerosis pharmacotherapy: a systematic review;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-09-09

2. Evaluation of corticoresistance in patients with Thyroid Eye Disease and use of Rituximab as a second-line treatment;2024-08-16

3. Bayesian network analysis of drug treatment strategies for thyroid associated ophthalmopathy;International Ophthalmology;2024-08-04

4. Long-Term Outcomes following Teprotumumab for Thyroid Eye Disease;Clinical Thyroidology®;2024-08-01

5. Effectiveness of Different Treatment Modalities in Initial and Chronic Phases of Thyroid Eye Disease: A Systematic Review With Meta-analysis;The Journal of Clinical Endocrinology & Metabolism;2024-07-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP